Ben J. Uttenthal

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Journal: Bone marrow transplantation
Published: April 26, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances
Published: January 21, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances
Published: January 21, 2026

Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells.

Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells.

Journal: British journal of haematology
Published: October 17, 2025

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.

Journal: British journal of haematology
Published: October 10, 2025

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Journal: HemaSphere
Published: September 05, 2025

Transient imaging changes accompany 'spinal ICANS' following CAR T-cell therapy for large B-cell lymphoma in adults.

Transient imaging changes accompany 'spinal ICANS' following CAR T-cell therapy for large B-cell lymphoma in adults.

Journal: British journal of haematology
Published: June 28, 2025

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.

Journal: HemaSphere
Published: February 13, 2024

Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.

Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.

Journal: British journal of haematology
Published: February 06, 2024

Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.

Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.

Journal: Blood cancer journal
Published: December 01, 2023

Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.

Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.

Journal: The lancet. Gastroenterology & hepatology
Published: November 18, 2023

Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.

Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.

Journal: British journal of haematology
Published: July 08, 2023
Showing 1-12 of 18

Last Updated: 09/26/2026